PCDE + PE + bevacizumab

PCDE + PE + bevacizumab is a combination regimen used in oncology, most likely for the treatment of advanced or metastatic cancers such as non-small cell lung cancer (NSCLC) or other solid tumors. In this context: - "PCDE" and "PE" are abbreviations for chemotherapy regimens. While the exact composition of "PCDE" is not standardized in major guidelines, "PE" commonly refers to cisplatin plus etoposide, a standard platinum-doublet chemotherapy backbone. - Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and tumor blood vessel formation[1][6]. This combination leverages cytotoxic effects from chemotherapy with antiangiogenic activity from bevacizumab to improve progression-free survival and overall outcomes in certain cancers[2][7]. The regimen may be under investigation or used off-label depending on regional protocols.